The role of Ras and other low molecular weight guanine nucleotide (GTP)-binding proteins during hematopoietic cell differentiation

Cellular and Molecular Life Sciences

Volumn 57, Issue 13-14, 2000, Pages 1950-1963

  Scheele, J S ^a   Rapple D ^a   Lubbert M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

ARF; Cell differentiation; Gene expression; Rab; Rad; Ran; Rap; Ras; Rho

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; RAS PROTEIN;

ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL SECRETION; CELL TRANSPORT; GENE CONTROL; GENE EXPRESSION; HEMATOPOIETIC CELL; HUMAN; LEUKEMIA; MOLECULAR WEIGHT; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHUMAN; ONCOGENE RAS; ORGANOGENESIS; POINT MUTATION; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0034489805     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00000675     Document Type: Article

References (154)

1. G proteins: Transducers of receptor generated signal
2. The GTPase superfamily: Conserved structure and molecular mechanism
3. The cellular functions of small GTP-binding proteins
4. Emerging concepts in the Ras superfamily of GTP-binding proteins
5. The Ras superfamily of GTPases
6. Increasing complexity of Ras signalling
7. Increasing complexity of the Ras signalling pathway
8. Regulation of Ras-mediated signalling: More than one way to skin a cat
9. All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ra1
10. Activation of the ERK/MAPK pathway by an isoform of rap1GAP associated with Gα (1)
11. Modulation of rap activity by direct interaction of G α(o) with Rap1 GTPase-activating protein
12. Ras-GRP, a Ras guanyl nucleotide-releasing protein with calcium- and diacylglycerol-binding motifs
13. A family of cAMP-binding proteins that directly activate Rap1
14. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP
15. RhoGEF, a GTPase activating protein for G12 and G13
16. The ras protein family: Evolutionary tree and role of conserved amino acids
17. The ras superfamily of GTP-binding proteins: Guidelines on nomenclature
18. The structure of Ras protein - A model for a universal molecular switch
19. Proteins regulating Ras and its relatives
20. The Ras signal transduction pathway
21. Ras genes
22. The GTPase superfamily: Conserved structure and molecular mechanism
23. Guanine nucleotide exchange factors: Activators of the Ras superfamily of proteins
24. Ras in signal transduction
25. Protein modification: New clue to ras lipid glue
26. Ras oncogenes in human cancer: A review
27. Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules
28. Decreased phosphorylation of a low molecular weight protein by cGMP-dependent protein kinase in variant HL-60 cells resistant to nitric oxide- and cGMP-induced differentiation
29. Deficient post-translational processing of Rap 1A in variant HL-60 cells
30. The pathway to signal achievement
31. The 3Rs of life: Ras, Raf and growth regulation
32. Complex formation between RAS and RAF and other protein kinases
33. Complexes of Ras. GTP with Raf-1 and mitogen-activated protein kinase kinase
34. Normal and oncogenic p21ras proteins bind to to the amino-terminal regulatory domain of c-Raf-1
35. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro
36. Mammalian Ras interacts directly with the serine/threonine kinase Raf
37. The complexity of Raf-1 regulation
38. Mitogenic signalling of Ras is regulated by differential interaction with Raf isozymes
39. Extracellular signals and reversible protein phosphorylation: What to Mek of it all
40. Erks: Their fifteen minutes has arrived
41. The SRF accessory protein Elk 1 contains a growth factor-regulated transcriptional activation domain
42. SRE: A growth factor responsive transcriptional regulator
43. Structural and biochemical analysis of Ras-effector signaling via Ra1GDS
44. Incidence and characterization of MLL gene (11q23) rearrangements in acute myeloid leukemia M1 and M5
45. A human protein selected for interference with Ras function interacts directly with Ras and competes with Raf1
46. KSR, a novel protein kinase required for RAS signal transduction
47. Regulation of the protein kinase Raf-1 by oncogenic Ras through phosphatidylinositol 3-kinase, Cdc42/Rac and Pak
48. Interleukin-9-induced expression of M-Ras/R-Ras3 oncogene in T-helper clones
49. TC21 and Ras share indistinguishable transforming and differentiating activities
50. Identification of a Ras-related protein that is a cAMP-dependent protein kinase substrate and is phosphorylated during chemically induced differentiation
51. Chemically induced murine erythroleukemia cell differentiation is severely impaired when cAMP-dependent protein kinase activity is repressed by transfected genes
52. Ras mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia but are prevalent in chronic myelomonocytic leukemia
53. The pattern of mutational involvement of ras genes in human hematologic malignancies determined by DNA amplification and direct sequencing
54. The molecular genetics of Philadelphia chromosome-positive leukemias
55. Genetic requirement for ras in the transformation of fibroblasts and hematopoietic cells by the bcr-abl oncogene
56. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein
57. Abl and Bcr are multifunctional regulators of the Rho GTP-binding protein family
58. Chronic myelomonocytic leukemia: Tel-a-kinase what ETS all about
59. Fusion of PDGF receptor to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
60. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia
61. Cloning of the ALL-1 fusion partner, the AF-6 gene, involved in acute myeloid leukemias with the t(6;11) chromosome translocation
62. Identification of AF-6 and canoe as putative targets for ras
63. The catalytic domain of the neurofibromatosis type gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae
64. Loss of NF1 result in activation of the ras signaling pathway and leads to aberrant growth in haematopoietic cells
65. NF1 deficiency causes ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia
66. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders
67. SSCP detection of N-ras promoter mutations in AML-patients
68. The RAS gene family and human carcinogenesis
69. Ras gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders and myelodysplastic syndromes
70. Analysis of ras gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes
71. N-RAS gene activation in acute myeloid leukemia: Association with expression of Interleukin-6
72. Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan
73. Analysis of ras gene mutations in childhood myeloid leukaemia
74. N-ras gene mutations in childhood acute non lymphoblastic leukemia
75. Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia
76. Mutations of the RAS genes in childhood acute myeloid leukemia, myelodysplastic syndrome and juvenile chronic myelocytic leukemia
77. Analysis of RAS oncogene mutations in human lymphoid malignancies
78. N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis
79. Alteration of N-ras gene mutation after relapse in acute lymphoblastic leukemia
80. Mutational analysis of the N-ras gene in acute lymphoblastic leukemia: A study of 125 Japanese pediatric cases
81. RAS gene activation in a minor proportion of the blast population in acute myeloid leukemia
82. Co-incident N and K ras gene mutations in a case of AML, restricted to differing cell lineages
83. Relapse cell population differs from acute onset clone as shown by absence of the initially activated N-ras oncogene in a patient with acute myelomonocytic leukemia
84. Mutational activation of the N-RAS oncogene assessed in primary clonogenic culture of acute myeloid leukemia (AML): Implications for the role of N-RAS mutation in AML pathogenesis
85. Sequential aquisition of trisomy 8 and N-RAS mutation in acute myeloid leukaemia demonstrated by analysis of isolated leukaemic colonies
86. Prognostic importance of mutations in the ras-proto-oncogenes in de novo acute myeloid leukemia
87. The incidence and prognostic significance of mutations in codon 13 of the N-ras gene in acute myeloid leukemia
88. N-ras mutations in adult de novo acute myelogenous leukemia: Prevalence and clinical significance
89. Analysis of mutations of neurofi bromatosis type 1 gene and N-ras gene in acute myelogenous leukemia
90. The non-random distribution of point mutations in leukaemia and myelodysplasia - A possible pointer to their aetiology
91. Clonal analysis of N-ras gene activation in acute myeloid leukemia
92. Mutant ras promotes haemopoietic cell proliferation or differentiation in a cell-specific manner
93. Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes
94. Reversible abrogation of IL-3 dependence by an inducible H- RAS oncogene
95. Interleukin-3 mRNA stabilization by a trans-acting mechanism in autocrine tumors lacking interleukin-3 gene rearrangements
96. Acquisition of interleukin-3 independence in FDC-P2 cells after transfection with the activated c-H-ras gene using a bovine papillomavirus-based plasmid vector
97. Inhibition of p21ras activation blocks proliferation but not differentiation of interleukin-3-dependent myeloid cells
98. Autocrine interleukin-1β production in leukemia: Evidence for the involvement of mutated RAS
99. Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6
100. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6
101. N-RAS mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome
102. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: A 10-year follow-up
103. Clonal analysis of myelodysplastic syndromes: Evidence of multipotent stem cell origin
104. Mechanisms of ras mutation in myelodysplastic syndrome
105. Retrospective analysis of ras gene activation in myeloid leukemic cells using polymerase chain reaction
106. Longitudinal analysis of point mutations of the N-ras proto-oncogene in patients with myelodysplasia using archival blood smears
107. Mutant N-RAS induces erythroid lineage dysplasia in human CD34 + cells
108. Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice
109. GTPase activating proteins
110. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants
111. Guanine nucleotide exchange factors: A family of positive regulators of Ras and relared GTPases
112. Molecular cloning of cDNAs encoding guanine nucleotidereleasing factor for Ras p21
113. Influence of guanine nucleotides on complex formation between Ras and CDC25 proteins
114. Identification of murine homologs of the Drosophila son of sevenless gene: Potential activators of ras
115. Signal transduction: How receptors turn Ras on
116. Membrane-targeting potentiates guanine nucleotide exchange factor CDC25 and SOS1 activation of Ras transforming activity
117. Membrane targeting of the nucleotide exchange factor SOS is sufficient for activating the Ras signaling pathway
118. Vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells
119. Tyrosine kinase stimulated guanine nucleotide exchange activity of Vav in T cell activation
120. Direct stimulation of Vav guanine nucleotide exchange activity for Ras by phorbol esters and diglycerides
121. Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor
122. Vav2 is an activator of Cdc42, Racl, and RhoA
123. Purification and characteriztation from bovine brain cytosol of proteins that regulate the GDP/GTP exchange reaction of smg p21, ras p21-like GTP-binding proteins
124. Both stimulatory and inhibitory GDP/GTP exchange proteins, smg GDS and rho GDI, are active on multiple small GTP-binding proteins
125. Translocation of Ki-ras p21 between membrane and cytoplasm by smg GDS
126. Molecular cloning and characterization of a novel type of regulatory protein for smg p25A, a ras p21-like GTP-binding protein
127. Purification and characterization from bovine brain cytosol of a novel regulatory protein inhibiting the dissociation of GDP from and the subsequent binding of GTP to rhoB p20, a ras p21-like GTP-binding protein
128. GDP-dissociation inhibitor prevents intrinsic and GTPase activating protein-stimulated GTP hydrolysis by the Rac GTP-binding protein
129. Post-translational modifications of the C-terminal region of the rho protein are important for its interaction with membranes and the stimulatory and inhibitory GDP/GTP exchange proteins
130. Biologically active lipids are regulators of Rac-GDI complexation
131. Translocation of Rac correlates with NADPH oxidase activation: Evidence for equimolar translocation of oxidase components
132. Activation of NADPH oxidase involves the dissociation of p21rac from its inhibitory GDP/GTP exchange protein (rhoGDI) followed by its translocation to the plasma membrane
133. Role of the rac1p21-GDP-dissociation inhibitor for rho heterodimer in the activation of the superoxide-forming NADPH oxidase of macrophages
134. Human cDNAs rap1 and rap2 homologous to the Drosophila gene Dras3 encode proteins closely related to ras in the effector region
135. cAMP activates MAP Kinase and ELK-1 through a B-Raf and Rap1 dependent pathway
136. Determination of absolute amounts of GDP and GTP bound to Ras in mammalian cells: Comparison of parental and Ras-over-producing NIH 3T3 fibroblasts
137. A decrease in the intracellular guanosine 5′-triphosphate concentrationis necessary for granulocytic differentiation of HL-60 cells, but growth cessation and differentiation are not associated with a change in the activation state of Ras, the transforming principle of HL-60 cells
138. Isolation and characterization of HL-60 cells resistant to nitroprusside-induced differentiation
139. Identification of tuberin, the tuberous sclerosis-2 product
140. The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis
141. The GTPase Rho has a critical regulatory role in thymus development
142. Different functions of the GTPase Rho in prothymocytes and late pre-T cells
143. Loss of Rho function in the thymus is accompanied by the development of thymic lymphoma
144. Molecular dissection of the secretory pathway
145. K-Ras is essential for the development of the mouse embryo
146. The murine N-ras gene is not essential for growth and development
147. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranyl-geranylated RhoB
148. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras
149. Mutations of the N-ras gene in juvenile chronic myelogenous leukemia
150. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias
151. Oncogenes in multiple myelomapoint mutations of N-Ras
152. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations. Analysis of the Eastern Cooperative Oncology Group Phase III Trial
153. N-ras genes are not mutated in Hodgkin and Reed Sternberg cells: Results from single-cell polymerase chain reaction examinations
154. Mutation of the ras genes is a rare genetic event in the histologic transformation of follicular lymphoma